Table 2 Findings from electrocardiography, echocardiography, and cardiovascular magnetic resonance imaging examinations at presentation of the whole study cohort and participants with CS and GCM
All patients (n = 92) | CS (n = 71) | GCM (n = 21) | p | |
|---|---|---|---|---|
ECG | ||||
Atrial fibrillation | 3 (30) | 2 (3) | 1 (5) | 0.512 |
HR (bpm) | 65 (54–78) | 62 (50–77) | 75 (63–93) | 0.007 |
PQ (ms) | 180 (160–212) | 186 (151–212) | 175 (163–224) | 0.947 |
High-grade AVB | 19 (21) | 17 (24) | 2 (9) | 0.223 |
Right BBB | 21 (23) | 16 (23) | 5 (24) | 0.764 |
Left BBB | 11 (12) | 11 (15) | 4 (19) | 0.108 |
Q-wave | 5 (5) | 3 (4) | 2 (10) | 0.281 |
Frequent PVCs | 17 (18) | 11 (15) | 6 (28) | 0.176 |
Echocardiography | ||||
LV EF (%) | 40 (27–55) | 45 (30–55) | 30 (20–41) | 0.002 |
LV ED diameter (mm) | 56 (51–62) | 56 (51–62) | 54 (51–61) | 0.360 |
LV ED volume (ml) | 139 (107–181) | 155 (108–209) | 124 (105–147) | 0.055 |
LV DD | 36 (39.1) | 22 (31) | 14 (67) | 0.010 |
RV dysfunction | 28 (30.4) | 17 (24) | 11 (52) | 0.026 |
sPAP (mmHg) | 30 (25–40) | 29 (23–40) | 40 (30–45) | 0.050 |
MRI | ||||
N = 58 | N = 46 | N = 12 | ||
LV ED volume (ml) | 171 (135–232) | 162 (130–232) | 193 (159–249) | 0.075 |
LV ES volume (ml) | 139 (85–181) | 90 (76–203) | 150 (105–157) | 0.376 |
LV EF (%) | 43 (32–57) | 50 (35–60) | 30 (22–42) | 0.022 |
RV ED volume (ml) | 162 (123–225) | 158 (97–217) | 188 (139–247) | 0.741 |
RV ES volume (ml) | 106 (77–200) | 101 (58–227) | 119 (92–186) | 0.252 |
RV EF (%) | 48 (26–60) | 52 (39–62) | 29 (24–45) | 0.031 |
Delayed enhancement | 54 (93) | 43 (93) | 11 (92) | 1 |